TrACER Study: Changing Prescription Order Systems to Lower Risk of Febrile Neutropenia in Patients Starting Chemotherapy
- The PCORI Strategic Plan
- Clinical Effectiveness and Decision Science
- Dissemination and Implementation
- Evaluation and Analysis
- Healthcare Delivery and Disparities Research
- PCOR Infrastructure & Innovation
- Our Vision & Mission
- Financial Statements and Reports
- The PCORI Strategic Plan
- Board of Governors
- Methodology Committee
- Authorizing Law
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
- Past Opportunities to Provide Input
- Executive Team
- Office of the Executive Director
- Program Support and Information Management
- Staff Conflict of Interest Disclosures
Some patients who receive chemotherapy develop a serious health problem called febrile neutropenia (FN), which involves having a fever and a low number of a type of white blood cells. Having a low number of white blood cells puts patients at risk for infection.
Different types of chemotherapy can put patients at different levels of risk for FN. When patients get chemotherapy that can create a high risk of FN, a type of medicine called colony-stimulating factor (CSF) can help prevent it. A doctor must prescribe this medicine. Many doctors use computer-based systems to order prescriptions for their patients.
The PCORI-funded TrACER study, led by a team from the Fred Hutchinson Cancer Research Center, tested whether adding information to a prescription order system would make it easier for doctors to follow practice guidelines and chemotherapy patients to get the medicine to prevent FN.
Nearly 3,000 participants from 32 cancer clinics were a part of the study. The study included adults aged 18 and older with breast, lung, or colorectal cancer who were getting chemotherapy at one of the 32 study cancer clinics and who spoke English or Spanish.
The research team found adding standing physician orders in the prescription order system did not significantly change the way doctors prescribed CSF for patients on high or low FN risk chemotherapy.
The research team presented its results at the 2022 American Society of Clinical Oncology Annual Meeting.
This trial also studied whether CSFs are effective for patients starting chemotherapy that have a medium risk of FN.
Posted: July 7, 2022
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.